To see if these differences were due to the overrepresentation of IBM patients in the anti‐NT5C1A antibody seropositive group, we performed a similar analysis that removed the 249 patients with IBM and thus looked at 240 non‐IBM IIMs (Table 2). The gene discussed is NT5C1A; the disease is inclusion body myositis.